Efficacy and Tolerability of a New Latanoprost 0.005%BAK-Free Nanoemulsion: A Nonrandomized Open-Label Trial

Estudio clínico

3388 3389 3392 3378

Palabras claves:

BAK-free, glaucoma, latanoprost, nanoemulsion, superficieocular, toxicidad

Estudios relacionados

Difluprednate 0.05% twice a day vs prednisolone acetate 1% 4 times a day forcataract postsurgical inflammation treatment:noninferiority trial

Latanoprost en nanoemulsión: una nueva opción terapéutica

A Comparative Study of Difluprednate 0.05% Nanoemulsion Vs Prednisolone Acetate 1% + Phenylephrine 0.12% Suspension on Postoperative Inflammation Treatment Following Cataract Surgery

(2018) Efficacy and tolerability of a new thermostable formulation of latanoprost in nanoparticles

Eficacia y tolerabilidad de una nueva formulación termoestable de latanoprost en nanopartículas

(2019) Efficacy and tolerability of a new thermostable formulation of latanoprost in nanoparticles